-

Bakkt Holdings Stock News: Robbins LLP Investigates Bakkt Holdings, Inc. (BKKT) f/k/a VPC Impact Acquisition Holdings (VIH) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Bakkt Holdings, Inc. (NYSE: BKKT, BKKTWS) f/k/a VPC Impact Acquisition Holdings (NASDAQ: VIHAU, VIH, VIHAW) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in connection with the Offering Documents in support of the Company's initial public offering ("IPO").

If you would like more information about our investigation into Bakkt Holdings, Inc.'s misconduct, click here.

What is this Case About: According to the complaint filed against Bakkt, Bakkt was formerly known as VPC Impact Acquisition Holdings and operated as a special purpose acquisition company. On October 15, 2021, Bakkt and Legacy Bakkt completed a business combination. Bakkt changed its name to Bakkt Holdings Inc. and began operating a digital asset platform that enables consumers to buy, sell, convert, and spend digital assets. However, the Offering Documents were negligently prepared. Specifically, the Offering Documents and defendants failed to disclose that the Company had defective financial controls and as such, there were errors in its financial statements related to the miscalculation of certain shares issued prior to the business combination. The Company downplayed the scope and severity of these issues and overstated its remediation of its defective financial controls.

On November 22, 2021, just a month after assuring investors it had remediated its defective financial controls, Bakkt disclosed it would have to restate certain of its previously-issued financial statements because of errors related to the misclassification of certain shares issued prior to the business combination. On this news, shares of Bakkt fell $2.70 per share, or 13.69%, to close at $17.02 per share on November 22, 2021. At the time the complaint was filed, Bakkt's Class A common stock was trading between $4.00 to $5.00 per share, trading below its initial value from the business combination.

Next Steps: If you acquired shares of Bakkt Holdings, Inc. (BKKT) between March 31, 2021 and November 19, 2021, you have options. Contact us for more information about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Bakkt Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:BKKT

Release Summary
Bakkt Holdings Stock News: Robbins LLP Investigates Bakkt Holdings, Inc. (BKKT) f/k/a VPC Impact Acquisition Holdings (VIH) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom